Introduction {#section5-1758835919889003}
============

MBC is a rare disease, which has different clinicopathological and immunohistochemical features from FBC.^[@bibr1-1758835919889003][@bibr2-1758835919889003][@bibr3-1758835919889003]--[@bibr4-1758835919889003]^ According to the latest data from the American Cancer Society, it accounts for about 0.98% and 1.18% of breast cancer morbidity and mortality, respectively.^[@bibr5-1758835919889003]^ The incidence of MBC has increased by 20--25% in the past few decades and continues to rise,^[@bibr6-1758835919889003],[@bibr7-1758835919889003]^ and even reached 15% in some specific populations.^[@bibr8-1758835919889003]^ The prognosis of MBC is worse than that of female patients due to older age and advanced stage at diagnosis.^[@bibr9-1758835919889003][@bibr10-1758835919889003]--[@bibr11-1758835919889003]^ Distant metastasis is an important factor influencing the prognosis of breast cancer. Nearly 20--30% of breast cancer patients with early age will finally develop metastatic lesions after diagnosis,^[@bibr12-1758835919889003],[@bibr13-1758835919889003]^ and 90% of breast cancer deaths are caused by metastasis leading to resistance to treatment.^[@bibr14-1758835919889003]^ Two previous studies based on the Surveillance, Epidemiology and End results (SEER) database have shown that stage IV accounts for about 7--9% of all MBC patients.^[@bibr15-1758835919889003][@bibr16-1758835919889003]--[@bibr17-1758835919889003]^ Because distant solid organ metastasis data in the SEER database was collected from 2010, previous studies were unable to study the specific metastasis sites of stage IV MBC patients.

Therefore, we identified MBC data recorded from 2010 to 2015 in the SEER database for this study. We studied metastatic MBC patients horizontally and longitudinally to determine their clinicopathological features and differences from metastatic FBC patients, and, at the same time, to determine independent factors affecting the prognosis of MBC patients.

Methods {#section6-1758835919889003}
=======

Patient selection {#section7-1758835919889003}
-----------------

For this study, we signed the SEER research data agreement to access SEER information with the username10067-Nov2018. Data were obtained following approved guidelines. The ethics committees considered this research to be on nonhuman subjects because the subjects were patients who had been researched by the United States Department of Health and Human Services and were publicly accessible and deidentified. Thus, this study was exempted by the ethics committee of the Third Affiliated Hospital of Soochow University.

The SEER database is one of the world's largest open cancer databases, established by the National Cancer Institute of the United States, and accounts for about 28% of the U.S. population. The data we selected came from Incidence-SEER 18 Registries Custom Data (with additional treatment fields), released April 2019, based on the November 2018 submission. MBC patients with definite metastasis from 1 January 2010 to 31 December 2015 were included in this study. The specific screening process is shown in [Figure 1](#fig1-1758835919889003){ref-type="fig"}. In short, we excluded patients whose age, race, survival time, pathological diagnosis, and metastasis were unknown, and whose pathological results were from autopsy or death certificate.

![Flowchart of patient selection.\
Detailed selection of MBC and FBC patients diagnosis at 2010--2015 from SEER database.\
FBC, female breast cancer; MBC, male breast cancer; SEER, surveillance, epidemiology and end results database.](10.1177_1758835919889003-fig1){#fig1-1758835919889003}

Variable classification {#section8-1758835919889003}
-----------------------

Age at diagnosis, race, primary site, laterality, grade, breast subtype, chemotherapy, radiation, surgery, and metastasis were obtained from the database. Age was divided into \<60 years old and ⩾60 years old. Metastasis of distant organs is defined in SEER as the state of metastasis of distant organs at the time of the first diagnosis of cancer. Distant metastatic sites included bone, brain, liver, and lung, according to the different metastatic sites, the distant metastasis was divided into 15 groups, which were single organ metastasis (bone, liver, brain, lung), two kinds of organ metastasis (bone and liver, bone and brain, bone and lung, liver and brain, liver and lung, brain and lung), three kinds of organ metastasis (bone, liver and brain; bone, liver and lung; bone, brain and lung; liver, brain and lung), and four organs metastasis (bone, liver, brain and lung). The degree of differentiation of tumors was divided into three groups: grade I (well differentiated) and grade II (moderately differentiated), grade III (poorly differentiated) and grade IV (undifferentiated), and unknown.

Statistical analysis {#section9-1758835919889003}
--------------------

We use descriptive statistics to summarize demographic and clinical variables. Chi-squared test or Fisher's exact test was used to compare the clinicopathological characteristics between different cohorts. Kaplan--Meier curves and log-rank test were conducted to analyze the overall survival (OS) of different metastasis organs in MBC and FBC patients. In addition, we use univariate and multivariate Cox proportional hazard models to find other variables that may affect prognosis. Statistical significance was considered at two-sided *p* value \<0.05. All data were obtained using SEER\*Stat Software version 8.3.5. All statistical analyses were performed using SPSS Statistics 25 (IBM, New York, NY, USA).

Results {#section10-1758835919889003}
=======

Population characteristics {#section11-1758835919889003}
--------------------------

From the SEER database, we finally identified 2754 MBC patients from 2010 to 2015. Among these MBC patients, 196 cases (7%) had distant metastasis, while 2558 cases (93%) did not. Compared with nonmetastatic MBC patients, MBC patients with distant metastasis had a higher proportion of \<60 years old (35% *versus* 25%), grade III--IV (40% *versus* 32%), and were more likely to receive chemotherapy (49% *versus* 36%) and radiotherapy (35% *versus* 26%), while the proportion of surgery (36% *versus* 94%), central portion of the breast (27% *versus* 42%), and Her2--/HR+ (58% *versus* 79%) was lower. Detailed patient clinical characteristics is summarized in [Table 1](#table1-1758835919889003){ref-type="table"}.

###### 

Clinical characteristics of male and female breast cancer.

![](10.1177_1758835919889003-table1)

  Characteristics    MBC without metastasis   MBC with metastasis   FBC with metastasis   *p* value[\*](#table-fn1-1758835919889003){ref-type="table-fn"}   *p* value[\*\*](#table-fn2-1758835919889003){ref-type="table-fn"}                   
  ------------------ ------------------------ --------------------- --------------------- ----------------------------------------------------------------- ------------------------------------------------------------------- ---- ---------- ----------
  Age                                                                                                                                                                                                                                0.001      0.013
   \<60              631                      25                    69                    35                                                                7016                                                                44              
   ⩾60               1927                     75                    127                   65                                                                8907                                                                56              
  Race                                                                                                                                                                                                                               0.060      0.403
   White             2078                     81                    146                   74                                                                12,033                                                              76              
   Black             360                      14                    39                    20                                                                2710                                                                17              
   Others            120                      5                     11                    6                                                                 1180                                                                7               
  Primary Site                                                                                                                                                                                                                       \<0.0001   \<0.0001
   Upper-outer       301                      12                    15                    8                                                                 3663                                                                23              
   Lower-outer       95                       4                     2                     1                                                                 832                                                                 5               
   Upper-inner       101                      4                     4                     2                                                                 975                                                                 6               
   Lower-inner       46                       2                     6                     3                                                                 546                                                                 3               
   Central portion   1082                     42                    53                    27                                                                937                                                                 6               
   Other             933                      36                    116                   59                                                                8970                                                                56              
  Laterality                                                                                                                                                                                                                         \<0.0001   0.601
   Left              1351                     53                    103                   53                                                                7798                                                                49              
   Right             1198                     47                    84                    43                                                                7380                                                                46              
   Other             9                        0                     9                     5                                                                 745                                                                 5               
  Grade                                                                                                                                                                                                                              \<0.0001   0.752
   I-II              1599                     63                    77                    39                                                                6469                                                                41              
   III-IV            829                      32                    79                    40                                                                6005                                                                38              
   Unknown           130                      5                     40                    20                                                                3449                                                                22              
   Breast Subtype                                                                                                                                                                                                                    \<0.0001   0.019
   Her2--/HR+        2019                     79                    114                   58                                                                8655                                                                54              
   Her2+/HR--        21                       1                     5                     3                                                                 1205                                                                8               
   Her2+/HR+         260                      10                    30                    15                                                                2333                                                                15              
   Triple negative   36                       1                     16                    8                                                                 1853                                                                12              
   Other             222                      9                     31                    16                                                                1877                                                                12              
   Chemotherapy                                                                                                                                                                                                                      \<0.0001   0.326
   No/Unknown        1641                     64                    100                   51                                                                7563                                                                47              
   Yes               917                      36                    96                    49                                                                8360                                                                53              
  Radiation                                                                                                                                                                                                                          0.012      0.406
   No/Unknown        1883                     74                    128                   65                                                                10,842                                                              68              
   Yes               675                      26                    68                    35                                                                5081                                                                32              
  Surgery                                                                                                                                                                                                                            \<0.0001   0.042
   No                160                      6                     126                   64                                                                11,340                                                              71              
   Yes               2398                     94                    70                    36                                                                4489                                                                28              
   Unknown           0                        0                     0                     0                                                                 94                                                                  1               

Comparison between MBC without metastasis and MBC with metastasis.

Comparison between MBC with metastasis and FBC with metastasis.

FBC, female breast cancer; MBC, male breast cancer.

In addition, we compared the clinicopathological features of patients with metastatic breast cancer between different genders ([Table 1](#table1-1758835919889003){ref-type="table"}). A total of 354,823 FBC patients were enrolled in the study, of which 15,923 were patients with distant metastasis, accounting for 4% of the total. Compared with metastatic FBC patients, MBC patients with distant metastasis had a higher proportion of ⩾60 years old (65% *versus* 56%), surgery (36% *versus* 28%), and central portion of the breast (27% *versus* 6%), while the proportion of Her2+/HR-- (3% *versus* 8%), triple negative (8% *versus* 12%), and was lower. There was no difference in race, laterality, grade, chemotherapy, and radiation.

Metastasis pattern {#section12-1758835919889003}
------------------

In the cohort of MBC with distant metastasis, the most common single site of metastases was bone with 81 cases, which takes up 41% of patients with distant metastasis, followed by lung metastasis with 26 (13%) cases, only 5 (3%) and 2 (1%) patients were with liver and brain metastasis, respectively. Most patients had distant metastasis of a single organ, accounting for 58%. There were 58 (30%) MBC patients who had distant metastasis of two organs, 43 of whom had bone and lung metastasis; 21 (12%) and 3 (2%) patients were diagnosed with three and four organ metastases, respectively. Detailed results are presented in [Table 2](#table2-1758835919889003){ref-type="table"}.

###### 

Comparison of organ metastasis patterns between male and female patients with breast cancer.

![](10.1177_1758835919889003-table2)

  Parameter                      Male   Female   *p* value        
  ------------------------------ ------ -------- ----------- ---- -----------------------------------------------------------------
  Bone metastasis only           81     41       6948        44   0.517[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Brain metastasis only          2      1        250         2    0.744[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}
  Liver metastasis only          5      3        1274        8    0.005[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Lung metastasis only           26     13       1848        12   0.471[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Bone and brain                 4      2        298         2    1[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}
  Bone and liver                 9      5        1483        9    0.023[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Bone and lung                  43     22       1716        11   \<0.0001[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Brain and liver                1      1        47          0    1[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}
  Brain and lung                 0      0        133         1    0.415[\*\*\*](#table-fn6-1758835919889003){ref-type="table-fn"}
  Liver and lung                 1      1        433         3    0.094[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}
  Bone, brain, and liver         1      1        118         1    1[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}
  Bone, brain, and lung          9      5        205         1    \<0.0001[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Bone, liver, and lung          10     5        895         6    0.754[\*](#table-fn4-1758835919889003){ref-type="table-fn"}
  Brain, liver, and lung         1      1        55          0    1[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}
  Bone, brain, liver, and lung   3      2        220         1    1[\*\*](#table-fn5-1758835919889003){ref-type="table-fn"}

Pearson chi-squared test.

Chi-squared test of continuity correction.

Fisher's exact test.

Additionally, we compared differences in metastasis patterns between males and females ([Table 2](#table2-1758835919889003){ref-type="table"}). The results showed that, in terms of single organ metastasis, the incidence of liver metastasis in MBC patients was significantly lower than that in FBC patients (3% *versus* 8%; *p* = 0.005). In terms of multiple organ metastasis, the incidence of both bone and liver metastasis in MBC patients was also lower than that in FBC patients (5% *versus* 9%; *p* = 0.023), while the proportion of both bone and lung in MBC patients was higher than that in FBC patients (22% *versus* 11%; *p* \< 0.0001), as well as in patients with bone, brain, and lung metastases (5% *versus* 1%; *p* \< 0.0001).

Survival and prognosis of MBC patients with metastasis {#section13-1758835919889003}
------------------------------------------------------

In metastatic MBC patients, there were mainly bone metastasis alone, lung metastasis alone, and simultaneous bone and lung metastasis, which accounted for more than three-quarters of the total metastasis population. Therefore, we included these three groups of people in the survival and prognostic analysis to explore the impact of distant metastasis on prognosis.

Kaplan--Meier analysis showed that there was no statistical difference in OS between MBC and FBC patients with distant metastasis ([Figure 2](#fig2-1758835919889003){ref-type="fig"}). However, there was significant difference between metastatic MBC and nonmetastatic MBC patients ([Figure 3](#fig3-1758835919889003){ref-type="fig"}). Moreover, there was no difference in survival among the three groups mentioned earlier.

![OS rate of MBC and FBC patients at different metastasis sites.\
(a) OS of bone alone metastasis between MBC and FBC patients, *p* = 0.05; (b) OS of lung alone metastasis between MBC and FBC patients, *p* = 0.772; (c) OS of both bone and lung metastasis between MBC and FBC patients, *p* = 0.766.\
FBC, female breast cancer; MBC, male breast cancer; OS, overall survival.](10.1177_1758835919889003-fig2){#fig2-1758835919889003}

![The survival difference among the different metastasis sites in MCB patients, *p* \< 0.0001.\
MBC, male breast cancer.](10.1177_1758835919889003-fig3){#fig3-1758835919889003}

We then performed multivariate analysis on variables that were meaningful in univariate analysis. As shown in [Table 3](#table3-1758835919889003){ref-type="table"}, multivariate analysis showed that age, grade, breast subtype, chemotherapy, surgery, and metastasis were independent factors for OS (*p* \< 0.0001). In details, patients ⩾60 years old had a worse OS than patients \<60 years old (HR:1.90, 95%CI:1.53--2.37, *p* \< 0.0001), and a worse prognosis was found in grade III--IV (HR:1.62, 95%CI:1.36--1.93, *p* \< 0.0001), breast subtype of triple negative (HR:3.32, 95%CI:2.10--5.26, *p* \< 0.0001) and patients with distant metastasis (HR:2.40, 95%CI:1.47--3.91, *p* \< 0.0001; HR:3.08, 95%CI:2.22--4.27, *p* \< 0.0001; HR:2.51, 95%CI:1.65--3.80, *p* \< 0.0001). Patients receiving chemotherapy and surgery had a better prognosis (HR:0.64, 95%CI:0.53--0.77, *p* \< 0.0001; HR:0.32, 95%CI:0.25--0.41, *p* \< 0.0001).

###### 

Univariate and multivariate survival analysis of male breast cancer patients with lung alone, bone alone and simultaneous lung and bone metastasis.

![](10.1177_1758835919889003-table3)

  Characteristics    Univariate analysis   Multivariate analysis                
  ------------------ --------------------- ----------------------- ------------ ----------
  Age                \<0.0001                                                   \<0.0001
   \<60                                    Reference                            
   ⩾60                                     1.90                    1.53--2.37   \<0.0001
  Race               0.028                                                      0.057
   White                                   Reference                            
   Black                                   1.24                    1.00--1.53   0.047
   Others                                  0.78                    0.51--1.20   0.256
  Primary Site       0.001                                                      0.103
   Upper-outer                             Reference                            
   Lower-outer                             0.64                    0.35--1.18   0.152
   Upper-inner                             1.24                    0.74--2.07   0.418
   Lower-inner                             0.95                    0.47--1.94   0.893
   Central portion                         1.24                    0.92--1.67   0.153
   Other                                   1.30                    0.97--1.75   0.078
  Laterality         0.170                 NA                                   
   Left                                                                         
   Right                                                                        
   Other                                                                        
  Grade              \<0.0001                                                   \<0.0001
   I--II                                   Reference                            
   III--IV                                 1.62                    1.36--1.93   \<0.0001
   Unknown                                 1.58                    1.18--2.13   0.002
  Breast Subtype     \<0.0001                                                   \<0.0001
   Her2--/HR+                              Reference                            
   Her2+/HR--                              0.90                    0.40--2.07   0.807
   Her2+/HR+                               1.24                    0.95--1.62   0.121
   Triple negative                         3.32                    2.10--5.26   \<0.0001
   Other                                   1.25                    0.96--1.61   0.094
  Chemotherapy       \<0.0001                                                   \<0.0001
   No/Unknown                              Reference                            
   Yes                                     0.64                    0.53--0.77   \<0.0001
  Radiation          0.518                 NA                                   
   No/Unknown                                                                   
   Yes                                                                          
  Surgery            \<0.0001                                                   \<0.0001
   No                                      Reference                            
   Yes                                     0.32                    0.25--0.41   \<0.0001
  Metastasis         \<0.0001                                                   \<0.0001
   None                                    Reference                            
   Lung Only                               2.40                    1.47--3.91   \<0.0001
   Bone Only                               3.08                    2.22--4.27   \<0.0001
   Lung and Bone                           2.51                    1.65--3.80   \<0.0001

Discussion {#section14-1758835919889003}
==========

In this study, we systematically analyzed the distant metastasis of MBC patients through the SEER database. The results showed that MBC patients not only had a higher distant metastasis rate than FBC patients, but also had different metastasis patterns. They had unique clinicopathological features. In addition, a multivariate analysis was conducted to determine independent factors affecting the prognosis of MBC patients.

The distant metastasis rate of MBC was 7% in our study, which was consistent with previous studies,^[@bibr15-1758835919889003],[@bibr16-1758835919889003]^ while the distant metastasis rate in FBC was 4%. The distant metastasis rate of MBC was 1.75 times higher than that of female patients. At present, it is believed that it is mainly lack of awareness of breast cancer in male patients or delays in diagnosis that might be the cause of this phenomenon.^[@bibr7-1758835919889003],[@bibr18-1758835919889003],[@bibr19-1758835919889003]^ A study found that only 29% of 100 Croatian MBC patients were diagnosed within 3 months of symptoms, compared with 58% of 500 Croatian FBC patients at the same time.^[@bibr20-1758835919889003]^ In addition, Hong and colleagues suggested that the prolonged period of symptom duration of MBC was also the reason for the difference in the rate of distant metastasis between MBC and FBC patients,^[@bibr17-1758835919889003]^ and NI and colleagues' study of 64 cases of male breasts without breast cancer showed columnar cell changes in 39 cases (61%), which was considered to be a transitional stage in the development of some low-grade ductal carcinoma *in situ* and invasive breast cancer.^[@bibr21-1758835919889003]^ In our opinion, in addition to the above reasons, differences in gene mutation may also cause this phenomenon. There are differences in genomics between MBC and FBC.^[@bibr22-1758835919889003],[@bibr23-1758835919889003]^ It was found that the mutation rate of CHEK2 c.1100delC in MBC was higher than that in FBC, and the mutation rate of CHEK2 c.1100delC was positively correlated with the rate of metastasis.^[@bibr24-1758835919889003],[@bibr25-1758835919889003]^

There were differences in age of diagnosis, primary site, grade, subtypes, and treatment methods (including chemotherapy, radiotherapy, and surgery) between metastatic MBC and nonmetastatic MBC. The difference in gene expression exists not only between different genders, but also at different ages of the same sex. Hallamies and colleagues found that median age of the *CHEK2*c.1100delC carriers was 56 years, and half of the patients were \<50 years old in MBC patients.^[@bibr24-1758835919889003]^ Poorly differentiated tumors seem to be more prone to distant metastasis, which seems to be associated with a higher frequency of local invasion of poorly differentiated tumors.^[@bibr26-1758835919889003]^ Previous studies have found that breast cancer subtypes were independent factors affecting the occurrence of metastasis. Compared with the other three subtypes, patients with luminal A (Her2--/HR+) had the lowest incidence of distant metastasis.^[@bibr27-1758835919889003],[@bibr28-1758835919889003]^ In our study, metastatic MBC patients had a lower proportion of luminal A compared with nonmetastatic patients; in contrast, the proportions of other three subtypes were higher. As expected, patients with metastatic MBC tend to lose the opportunity for surgery, and were more likely to choose radiotherapy and chemotherapy.

The median age of diagnosis of MBC was 5--10 years older than that of FBC patients in many studies.^[@bibr29-1758835919889003][@bibr30-1758835919889003]--[@bibr31-1758835919889003]^ This may be that the proportion of MBC patients with distant metastasis ⩾60 years old is higher than that of FBC patients. The rate of metastasis in the central portion of the breast in metastatic MBC was significantly higher than that in female patients, but on the contrary in the upper outer of the breast, which may be related to anatomical difference between male and female breasts. As with the findings reported by Li and colleagues,^[@bibr32-1758835919889003]^ there were differences in molecular subtypes in patients with metastatic breast cancer of different genders.

As far as we know, this is the first time that the distant metastasis patterns of MBC and FBC patients have been compared in detail through a large cancer database. Our study found that the metastasis rates of bone, lung, liver, and brain metastasis in metastatic MBC patients were 82%, 47%, 16%, and 11%, respectively. Under the same conditions, the metastasis rates of various organs in women were 75%, 35%, 28%, and 8%, respectively. Bone metastasis rates were higher than in previous studies, with bone metastasis rates of 50% in metastatic MBC patients in a previous German study,^[@bibr33-1758835919889003]^ and 75% in another study based on the SEER database.^[@bibr34-1758835919889003]^ However, the highest incidence of bone metastasis and the lowest incidence of brain metastasis were consistent with previous studies. Although the rate of single liver metastasis was only 3%, it seems that the rate of liver metastasis combined with other metastases was not low, accounting for 13% of the total metastases, and also in brain metastases (1% *versus* 10%). We believed that once a tumor had distant metastasis of one organ, it may accelerate metastasis in other parts, although single liver or brain metastasis was not common, but when the tumor had metastasis in other parts, it accelerated liver and brain metastases. This requires the attention of clinicians. We also found that, although there was no difference in the rate of single lung and bone metastasis between MBC and FBC patients, the risk of simultaneous bone and lung metastasis in male patients was twice as high as that in female patients. Male patients have a higher smoking rate, at about 1.5 times that of women.^[@bibr35-1758835919889003]^ Smoking is a risk factor for cancer metastasis, including bone and lung metastasis.^[@bibr36-1758835919889003],[@bibr37-1758835919889003]^ Studies have found that the liver microenvironment is an important factor affecting liver metastasis of breast cancer. For example, lysyl oxidase inhibits liver metastasis,^[@bibr38-1758835919889003]^ while osteopontin and vascular endothelial growth factor promote liver metastasis.^[@bibr39-1758835919889003],[@bibr40-1758835919889003]^ This may be one of the reasons for the difference in liver metastasis rate between male and female patients with breast cancer.

Although metastatic MBC patients had unique clinicopathological features and metastatic pattern, we found that there was no difference in OS compared with metastatic FBC patients. Our results were consistent with those of other similar studies, such as stage IV breast cancer patients,^[@bibr34-1758835919889003]^ gastric cancer patients with liver metastasis,^[@bibr41-1758835919889003]^ and colorectal signet ring cell carcinoma patients with distant metastasis.^[@bibr42-1758835919889003]^ Multivariate analysis showed that distant metastasis was an independent risk factor affecting the prognosis of MBC. Metastatic MBC patients had a worse OS rate compared with nonmetastatic MBC patients (*p* \< 0.0001). There was no survival difference between patients with single lung or bone metastasis and patients with both bone and lung metastasis. We also found that the prognosis of HER--/HR+ was similar to that of HER+/HR--, and that triple-negative breast cancer patients had the highest risk of death, which was consistent with previous studies, possibly because HER+ patients benefited from the use of trastuzumab.^[@bibr43-1758835919889003],[@bibr44-1758835919889003]^ In addition, age, chemotherapy, surgery, and histological grade were also important factors affecting the prognosis of MBC. Because there are fewer MBC patients, for a long time, the treatment of MBC refers to FBC.^[@bibr2-1758835919889003]^ Although radiotherapy seem to have no effect on prognosis in our cohort, we do not know what organs have received radiotherapy, and studies have shown that radiotherapy can improve the prognosis of MBC patients,^[@bibr45-1758835919889003][@bibr46-1758835919889003]--[@bibr47-1758835919889003]^ so this conclusion needs to be further verified.

Our research still has some limitations. Firstly, there are only liver, brain, lung, and bone metastasis in distant parenchymal organ metastasis in SEER database; however, it has been reported that MBC can also metastasize to other sites, such as oral mucosa,^[@bibr48-1758835919889003]^ or choroidal sites.^[@bibr49-1758835919889003]^ Secondly, reasons for the difference in breast cancer metastasis between men and women still need further exploration. Finally, our conclusions may apply only to patients from the United States.

To sum up, through this study, we found that metastatic MBC patients have unique clinicopathological features and metastatic patterns, and that these differed from metastatic FBC patients. However, there was no difference in prognosis between MBC and FBC patients with metastasis. Distant metastasis was an independent risk factor for the prognosis of MBC patients.
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